Linked research, clinical, and regulatory source pathways.
Company profile
About Charles River Laboratories
Charles River Laboratories uses Logica, an AI-powered drug development solution, to translate biological insights and accelerate pharmaceutical discovery and development.
Company description Charles River Laboratories official website
Primary marketDrug Discovery & Development
Commercial modelCommercial information available on request
Company presenceLinkedIn
Work at Charles River Laboratories?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
No clinical focus areas are currently listed.
Who it serves
No customer types are currently listed.
Deployment & integration
Deployment information is currently being developed.
Geographic context
MarketsNot currently listed
Company sourceOfficial website
Company milestones
Platform expansion
Company milestone context is currently being developed.
Partnerships
Recorded partners
- New England Patriots
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
No source-backed Company products are currently listed.
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Antisense oligonucleotide treatment following viral delivery of artificial SOD1-targeting miRNA shows improved efficacy in SOD1-G93A mice.Molecular therapy. Advances · Sep 10, 2026
Intra-CNS AAV9-GBA1 delivery yields species and route of administration differences in safety and transgene expression.Molecular therapy. Advances · Sep 10, 2026
Timing matters: Exon skipping therapy is most effective when initiated early in a mouse model of Duchenne muscular dystrophy.Molecular therapy. Nucleic acids · Sep 8, 2026
Early bone-formation response to sclerostin antibody is altered by prior antiresorptive treatment in ovariectomized rats.JBMR plus · Sep 1, 2026
Toxicologic Pathology Forum: ESTP/STP Working Group Opinion on the Evolving Landscape of New Approach Methodologies in Drug and Chemical Safety Development.Toxicologic pathology · Aug 28, 2026
Immunohistochemical Characterization of Intraocular Inflammation After Intravitreal Administration of Biologics to NHP and Minipigs: A Study Across Compounds.Toxicologic pathology · Aug 22, 2026
Clinical validation
Clinical-trial records
Evaluate the Safety and Pharmacokinetic Profile of ETR028 and ETR029 in Healthy Adult SubjectsNCT05572190 · Sponsor · UNKNOWN
Pharmacokinetics (PK) and Pharmacodynamics (PD) of Mayne Glucagon for Injection Compared With Glucagen® (Novo Nordisk) in Healthy VolunteersNCT00745186 · Mentioned · COMPLETED
Human Mass Balance Study With BilastineNCT00572611 · Sponsor · COMPLETED
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
No Company-reported outcomes are currently listed.
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
No active leadership profiles are currently listed.
06 · Company updates
Updates from Charles River Laboratories
Recent articles published on Charles River Laboratories's official website.
No Company updates are currently listed.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Drug Discovery & Development
Companies using AI, machine learning, or computational biology to discover new drug candidates, identify drug targets, predict drug efficacy, or accelerate pharmaceutical development. Includes both small molecule and biologics development, precision oncology drug discovery, and AI-driven target identification and molecule design.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.